Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05218655 · ClinicalTrials.gov registry record · Phase 3
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
A Phase 3 study, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT05218655 is a Phase 3 study that has completed, run by PTC Therapeutics. The registered enrollment target is 101 participants.
The verdict
NCT05218655, a Phase 3 study, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.
Interventions
- DRUG Vatiquinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2022-06-22 |
| Est. Completion | 2025-04-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05218655
The ClinicalTrials.gov registry entry for NCT05218655 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vatiquinone is the first listed.
NCT05218655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05218655 about?
NCT05218655 is a clinical study titled "A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease". The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone become...
What is the current status of trial NCT05218655?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2022-06-22. Estimated completion is 2025-04-15.
What interventions are being tested in trial NCT05218655?
The interventions under investigation include: Vatiquinone (DRUG).
Who is sponsoring clinical trial NCT05218655?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.